 | | Vol. 10.31 – 4 October, 2024 |
| |
|
|
| In this short-term trial, tulisokibart was more effective than placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis.
[New England Journal of Medicine] |
|
|
|
 | | PUBLICATIONSListed by the impact factor of the journal |
|
|
|
| In this exploratory biomarker analysis of the BEACON Colorectal Cancer study, researchers characterized genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis.
[Nature Medicine] |
|
|
|
| By combining analysis of primary human intestinal resection material and intestinal organoids, the authors identified four distinct human tuft cell states, two of which overlap with their murine counterparts.
[Nature] |
|
|
|
| A pH and reactive oxygen species (ROS) dual-responsive autocatalytic release system was constructed to reverse the immunosuppressive microenvironment and potentiate colorectal cancer immunotherapy.
[Advanced Materials] |
|
|
|
| Investigators uncovered a novel regulatory mechanism where hyodeoxycholic acid and 12-ketodeoxycholic acid inhibited colonic inflammation by reducing the expression of transmembrane guanylate cyclase 1A in the colonic epithelium.
[Advanced Science] |
| |
|
|
Selenium was protective against radiation colitis through inhibiting X-ray-induced apoptosis, cell cycle arrest, and inflammation with the involvement of balancing the generation of reactive oxygen species after the irradiation.
[Advanced Science] |
| | Single cell multi-omics uncovered epigenetic alterations that accompany enteroendocrine cells (EEC) differentiation, identified STAT3 as a regulator of EEC specification, and discovered a rare cancer-specific cell type with enteric neuron-like characteristics.
[Cancer Research] |
|
|
|
| Scientists developed a hydrogel platform for confined copper depletion in BRAFV600E-mutant colorectal cancer cells, which effectively reversed dabrafenib/cetuximab resistance and enhancing therapeutic efficiency.
[Journal of Controlled Release] |
|
|
|
| Investigators performed a Phase I dose-escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib. This multicenter trial enrolled patients with metastatic ovarian cancer or microsatellite stable colorectal cancer.
[Cancer Immunology Research] |
|
|
|
| Researchers developed a bivalent DOTA-radiohapten, Lu-Gemini, that showed improved radiopharmacology for DOTA-based pretargeted radioimmunotherapy application.
[Journal of Nuclear Medicine] |
|
|
|
| Disruption in Wnt-Notch signaling was accompanied by the loss of intestinal stem cell compartment, increase in Bmi1 positive cells, loss of Olfm4/Lgr5 positive cells, and reduced secretory Paneth cells and goblet cells in the intestinal crypts of p21TKO mice.
[Cell Death Discovery] |
|
|
|
|
| The authors provide an overview of intestinal tuft cells, providing insights into their development, signaling, and interaction modules in immunity and other states.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Investigators discuss how different diets and metabolic changes influence intestinal stem cells in homeostatic and pathological conditions, as well as tumorigenesis.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors describe the current and emerging clinical evidence supporting the use of neoadjuvant immune-checkpoint inhibitors in patients with DNA mismatch repair deficiency and proficient DNA mismatch repair colorectal cancer, and the potential advantages of such an approach.
[Nature Reviews Clinical Oncology] |
|
|
|
|
| Researchers from the University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center were awarded a $3 million grant from the National Institutes of Health to improve follow-up care for colorectal cancer screening in underserved populations.
[UCLA Health] |
|
|
|
| Abivax SA announced the first patient was enrolled in its Phase IIb ENHANCE-CD trial evaluating obefazimod in patients with Crohn’s disease.
[Abivax] |
|
|
|
|
| November 6-8, 2024
London, England, United Kingdom |
|
|
|
|
|
| | IFOM ETS – The AIRC Institute of Molecular Oncology – Milan, Italy |
|
|
|
| | Northwell Health – Manhasset, New York, United States |
|
|
|
| | University of Dundee – Dundee, Scotland, United Kingdom |
|
|
|
| | University of Würzburg – Würzburg, Germany |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
